BioWorld

Dec. 29, 2008

View Archived Issues

GSK Opts Out of Two Cancer Programs with Cytokinetics

Cytokinetics Inc. received some disappointing news just before the holidays, as longtime partner GlaxoSmithKline plc decided to take a pass on developing two early stage cancer compounds. (BioWorld Today) Read More

Paladin Labs Acquires ViRexx with Bankruptcy Financing

Read More

NewCo News: Start-up Firm Harvests Exosomes from Blood to Diagnose Cancer

Read More

BioWorld's Annual Report Ranks Top Execs' Pay

Read More

Holiday Notice

Read More

Other News To Note

Read More

Financings Roundup

Read More

Clinic Roundup

Read More

U.S. Patent Disclosures

Read More